Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginesatide dose escalation in anemic cancer patients
NCT00272662Phase 2Completed
- Sponsor
- Affymax, Inc.
- Start
- Jan 2006
- Primary completion
- Jun 2007
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 2, open-label trial of peginesatide (4 cohorts), sponsored by Affymax, Inc. Primary endpoint: Percentage of participants with a hemoglobin increase of >= 1 g/dL at 9 weeks. Started Jan 2006; status: completed.
02
Drugs
peginesatide
Beyond the preview
Go deeper on NCT00272662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272662.